Video

The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer

Author(s):

Bradley J. Monk, MD, FACS, FACOGRobert L. Coleman, MD, FACOG, FACS

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

Related Videos
5 KOLs are featured in this program
5 KOLs are featured in this program
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Related Content
Aparna Parikh, MD
July 19th 2024

Rezatapopt Takes Aim at Previously Untargetable p53 Allele to Treat Advanced Solid Tumors

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

FDA
July 3rd 2024

OncLive’s June Roundup of Key FDA Approvals in Oncology

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.
June 28th 2024

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

Susana Banerjee, MBBS, MA, PhD, FRCP, consultant medical oncologist, research lead, Gynaecology Unit, The Royal Marsden NHS Foundation Trust
June 21st 2024

Mirvetuximab Soravtansine Elicits Benefits in Ovarian Cancer Regardless of Dose Modifications